NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

The summary for the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required): The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

Federal Grant Title:	NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-21-237
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.853
CFDA Descriptions:	Information not provided
Current Application Deadline:	May 7th, 2024
Original Application Deadline:	May 7th, 2024
Posted Date:	May 19th, 2021
Creation Date:	May 19th, 2021
Archive Date:	June 12th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 21st, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-21-237.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Ge...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...; • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...; • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required); • Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed); • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic ...; • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical...; • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical...